Population pharmacokinetics and dosing regimen optimisation of lopinavir in Chinese adults infected with HIV

• DOI: 10.1111/bcpt.13154
• Publication Date: 2018-10-22T12:58:11Z
• Authors: Wan‐jie Niu; Tao Sun; Li Liu; Xiao‐qian Liu; Ren‐fang Zhang; Lin Yin; Jiang‐rong Wang; Xiao‐fang Jia; Hong‐Zhou Lu; Ming‐kang Zhong; Zheng Jiao; Li‐jun Zhang
• Keywords: Lopinavir; Lopinavir/ritonavir; Regimen; Ritonavir

Abstract Lopinavir (LPV) is a protease inhibitor (PI) for the treatment of human immunodeficiency virus (HIV) infections. Current studies on LPV are mainly focused Caucasians, and none have investigated population pharmacokinetics (PPK) in Chinese population. The present study aimed to develop PPK model oral adults who HIV‐infected. A total 460 concentrations from 174 patients received LPV/ritonavir (LPV/r) 400/100 mg orally every 12 hours (q12h) were analysed using non‐linear mixed‐effects modelling approach. Simulations concentration profile performed with different dosing regimens. one‐compartment first‐order absorption elimination process described data. estimated apparent clearance (CL/F) volume distribution (V/F) (% relative standard error [RSE]) 5.9 L/h (3%) 117 L (8%), respectively. Body‐weight was identified as covariate CL/F. In weighed between 45 115 kg q12h regimen, probability achieving target trough (C ) 1 mg/L >98% PI‐naïve C 4 <80% PI‐pretreated patients. This first pharmacokinetic characterise PK HIV infection. There no obvious ethnic differences Caucasian simulations demonstrated that regimen (LPV/r tablets) appears be sufficient but suboptimal Therefore, 800/200 recommended Further investigation dosage recommendation could helpful optimising therapy